(Q45745544)

15 December 2017

title

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection (English)

1 reference

15 December 2017

1 reference

1 reference

1 reference

1 reference

R J Gilson

1

1 reference

15 December 2017

K B Chopra

2

1 reference

15 December 2017

A M Newell

3

1 reference

15 December 2017

I M Murray-Lyon

4

1 reference

15 December 2017

M R Nelson

5

1 reference

15 December 2017

S J Rice

6

1 reference

15 December 2017

R S Tedder

7

1 reference

15 December 2017

J Toole

8

1 reference

15 December 2017

H S Jaffe

9

1 reference

15 December 2017

I V Weller

10

1 reference

15 December 2017

publication date

1 September 1999

1 reference

15 December 2017

Journal of Viral Hepatitis

published in

1 reference

15 December 2017

volume

6

1 reference

15 December 2017

issue

5

1 reference

15 December 2017

page(s)

387-395

1 reference

15 December 2017

The treatment of chronic viral hepatitis

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Famciclovir: review of clinical efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Carnitine deficiency induced by pivampicillin and pivmecillinam therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Detection of both hepatitis B e antigen and antibody in a single assay using monoclonal reagents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Hepatitis B reactivation after lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00182.X

10.1046/J.1365-2893.1999.00182.X

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017